Central serotonergic systems in the spontaneously hypertensive and Lewis rat strains that differ in the elevated plus-maze test of anxiety

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 2, 1997, Pages 775-784

  Kulikov, Alexander ^a,b   Aguerre, Sylvie ^a   Berton, Olivier ^a   Ramos, Andre ^a   Mormede, Pierre ^a   Chaouloff, Francis ^a,c  

^a INSERM   (France)

^b INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^c INSTITUT FRANÇOIS MAGENDIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE I 131; 5 HYDROXYINDOLEACETIC ACID; 8 HYDROXY 2 PROPYLAMINOTETRALIN; CITALOPRAM; KETANSERIN; QUIPAZINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; TRYPTOPHAN HYDROXYLASE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL BEHAVIOR; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MESENCEPHALON; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; STRAIN DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CITALOPRAM; FEMALE; HIPPOCAMPUS; HYDROXYINDOLEACETIC ACID; KETANSERIN; MALE; MESENCEPHALON; RATS; RATS, INBRED LEW; RATS, INBRED SHR; RECEPTORS, SEROTONIN; SEROTONIN; TRITIUM; TRYPTOPHAN HYDROXYLASE;

EID: 0030995485     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. 2 receptor down-regulation results in anxiolytic effects in the elevated plus-maze. Drug Dev. Res. 26: 287-297, 1992.
2. BLIER, P. AND D. E. MONTIGNY, C.: Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15: 220-226, 1994.
3. BOADLE-BIBER M. C.: Biosynthesis of serotonin. In Biology of Serotonergic Transmission, ed. by N. N. Osborne, pp. 63-94, John Wiley, New York, 1982.
4. BOUCHAHD T. J., JR.: Genes, environment, and personality. Science 264: 1700-1701, 1994.
5. BRADFORD, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
6. 1A) messenger ribonucleic acid abundance, and serotonin levels parallel the activity of the hypothalamo-pituitary-adrenal axis in rat. J. Neurochem. 59: 1062-1070, 1992.
7. 3H]ketanserin binding and an anxiolytic profile in the elevated X-maze. Br. J. Pharmacol. 107: 108P, 1992.
8. CARLSSON, M. AND CARLSSON, A.: In vivo evidence for a greater brain tryptophan hydroxylase capacity in female than in male rats. Naunyn-Schmiedebergs Arch. Pharmacol. 338: 345-349, 1988.
9. CHAOULOFF, F.: Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res. Rev. 18: 1-32, 1993.
10. 2 receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)2-aminopropane (DOI) increases brain tryptophan levels in the rat. Eur. J. Pharmacol. 214: 101-103, 1992.
11. 1A autoreceptors in Lewis and SHR rats. Neuropharmacology 36: in press, 1997.
12. CHAOULOFF, F., KULIKOV, A., SARRIEAU, A., CASTANON, N. AND MORMEDE, P.: Male Fischer 344 and Lewis rats display differences in locomotor reactivity, but not in anxiety-related behaviours: Relationship with the hippocampal serotonergic system. Brain Res. 693: 169-178, 1995.
13. CHOPIN, P. AND BRILEY, M.: Animal models of anxiety: The effect of compounds that modify serotonergic function. Trends Pharmacol. Sci. 8: 383-388, 1987.
14. 3H]imipramine. J. Pharmacol. Exp. Ther. 242: 364-371, 1987.
15. 1A receptor agonists: Recent developments and controversial issues. Psychopharmacology 121: 1-26, 1995.
16. FILE, S. E.: The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods 2: 219-238, 1980.
17. FILE, S. E.: The biological basis of anxiety. In Current Practices and Future Developments in the Pharmacotherapy of Mental Disorders, ed. by H. Y. Meltzer and D. Nerozzi, pp. 159-165, Elsevier, Amsterdam, 1991.
18. FILE, S. E., ZANGROSSI H., JR. AND ANDREWS, N.: Social interaction and elevated plus-maze tests: Changes in release and uptake of 5-HT and GABA. Neuropharmacology 32: 217-221, 1993.
19. FLINT, J., CORLEY, R., DEFRIES, J. C., FULKER, D. W., GRAY, J. A., MILLER, S. AND COLLLNS, A. C.: A simple genetic basis for a complex psychological trait in laboratory mice. Science 269: 1432-1435, 1995.
20. 3H]PAT. Nature 305: 140-142, 1983.
21. GRIEBEL, G.: 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research. Pharmacol. Ther. 65: 319-395, 1995.
22. HAMON, M., BOURGOIN, S., ARTAUD, F. AND E. L. MESTIKAWY, S.: The role of tryptophan uptake and tryptophan hydroxylase in the regulation of serotonin synthesis in the central nervous system. J. Physiol. (Paris) 77: 269-280, 1981.
23. HAMON, M., BOURGOIN, S., GOZLAN, H., HALL, M. D., GOETZ, C., ARTAUD, F. AND HORN, A. S.: Biochemical evidence for the 5-HT agonist properties of PAT (8-hydroxy-2-(di-n-propylamino)tetralin) in the rat brain. Eur. J. Pharmacol. 100: 263-276, 1984.
24. HANDLEY, S. L.: 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol. Ther. 66: 103-148, 1995.
25. HANDLEY, S. L. AND MCBLANE, J. W.: 5-HT drugs in animal models of anxiety. Psychopharmacology 112: 13-20, 1993.
26. HANDLEY, S. L. AND SINGH, L.: Neurotransmitters and shaking behaviour: More than a 'gut-bath' for the brain. Trends Pharmacol. Sci. 7: 324-328, 1986.
27. 1A receptor agonist, 8-OH-DPAT, preferentially activates cell body 5-HT autoreceptors in rat brain in vivo. Naunyn-Schmiedebergs Arch. Pharmacol. 338: 463-471, 1988.
28. 2 receptors in rat brain: An autoradiological study. Synapse 14: 324-331, 1993.
29. HUTSON, P. H., SARNA, G. S., O'CONNELL, M. T. AND CURZON, G.: Hippocampal 5-HT synthesis and release in vivo is decreased by infusion of 8-OH-DPAT into the nucleus raphe dorsalis. Neurosci. Lett. 100: 276-280, 1989.
30. IVERSEN, S. D.: 5-HT and anxiety. Neuropharmacology 23: 1553-1560, 1984.
31. JACOBS, B. L. AND KLEMFUSS, H.: Brainstem and spinal cord mediation of serotonergic behavioural syndrome. Brain Res. 100: 450-457, 1975.
32. JOHNSON, A. M.: The comparative pharmacological properties of selective serotonin re-uptake inhibitors in animals. In Selective Serotonin Re-uptake Inhibitors, ed. by J. P. Feighner and W. F. Boyer, pp. 37-70, John Wiley & Sons, Chichester, UK, 1991.
33. 1C. receptors and their therapeutic relevance. Curr. Opin. Invest. Drugs 2: 317-362, 1993.
34. 1C receptors. Br. J. Pharmacol. 94: 137-147, 1988.
35. 2C/2B receptor function. Neuropharmacology 33: 1581-1588, 1994.
36. 2A receptor, and 5-HT transporter binding in grouped and isolated Roman RHA and RLA rats: Relationships with behaviours in two models of anxiety. Psychopharmacology 121: 385-395, 1995.
37. LAHMANE, A. AND ARMARIO, A.: Differential responsiveness of inbred strains of rats to antidepressants in the forced swimming test: Are Wistar Kyoto rats an animal model of subsensitivity to antidepressants? Psychopharmacology 123: 191-198, 1996.
38. LESCH, K. P., AULAKH, C. S., WOLOZIN, B. L., TOLLIVER, T. J., HILL, J. L. AND MURPHY, D. L.: Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Mol. Brain Res. 17: 31-35, 1993.
39. 2 receptor binding sites. Mol. Pharmacol. 21: 301-314, 1982.
40. LUCKI, I., WARD, H. R. AND FRAZER, A.: Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. J. Pharmacol. Exp. Ther. 249: 155-164, 1989.
41. MAJ, J. AND MORYL, E.: Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor populations. J. Neural Transm. 88: 143-156, 1992.
42. 2 receptors in the dorsal hippocampus of male and female rats. Neuroendocrinology 54: 454-461, 1991.
43. NUTT, D.: The anxiety factor in depression. J. Psychopharmacol. 9: suppl., 185-189, 1995.
44. PELLOW, S., CHOPIN, P., FILE, S. E. AND BRILEY, M.: Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14: 149-167, 1985.
45. PINEYRO, G., BLIER, P., DENNIS, T. AND D. E. MONTIGNY, C.: Desensitisation of the neuronal 5-HT carrier following its long-term blockade. J. Neurosci. 14: 3036-3047, 1994.
46. RAMOS, A., BERTON, O., MORMEDE, P. AND CHAOULOFF, F.: A multiple-test study of anxiety-related behaviours in six inbred rat strains. Behav. Brain Res., 85: 57-69, 1997.
47. 1A agonists. J. Pharmacol. Exp. Ther. 273: 101-112, 1995.
48. 1B agonists. Synapse 1: 3-9, 1987.
49. 2 receptor subtypes. Mol. Pharmacol. 38: 594-598, 1990.
50. 1A receptor-related anxiolytics. Trends Pharmacol. Sci. 8: 432-437, (1987).
51. TREIT, D.: Animal models for the study of anti-anxiety agents: A review. Neurosci. Biobehav. Rev. 9: 203-222, 1985.
52. 1 recognition receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur. J. Pharmacol. 106: 271-282, 1984.
53. WIELAND, S., KREIDER, M. S., MCGONIGLE, P. AND LUCKI I.: Destruction of the nucleus raphe obscurus and potentiation of serotonin-mediated behaviors following administration of the neurotoxin 3-acetylpyridine. Brain Res. 520: 291-302, 1990.
54. 2 receptor-mediated responses. Eur. J. Pharmacol. 219: 261-269, 1992.